Plasma Cell Myeloma
24 drugs58,745 FAERS reportsMedDRA PT
GET
/api/v1/reaction/plasma-cell-myelomaReference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. The drugs below are ranked by how often this reaction appears on FAERS reports for each drug — high share does not mean the drug caused the reaction, and absence from this list does not mean the reaction never occurred. This is not a symptom checker.
DefinitionNLM MeSH D009101
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Source: U.S. National Library of Medicine — MeSH (Multiple Myeloma)
Drugs reporting Plasma Cell Myeloma (24)
Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.
- 1Selenious Acid550%
- 2Tetanus Toxin117%
- 3Belantamab41915%
- 4Belantamab Mafodotin41915%
- 5Copper Gluconate114%
- 6Selinexor1,15714%
- 7Ixazomib3,63613%
- 8Elotuzumab55911%
- 9Carfilzomib2,98911%
- 10Daratumumab3,8569.4%
- 11Pomalidomide7,9427.9%
- 12Isatuximab3476.6%
- 13Teclistamab1196.1%
- 14Talquetamab1075.8%
- 15Thalidomide2,0065.5%
- 16Melphalan1,2615.1%
- 17Dexamethasone14,1084.7%
- 18Plerixafor604.1%
- 19Lenalidomide16,9764.1%
- 20Idecabtagene Vicleucel474.1%
- 21Elranatamab313.5%
- 22Rolapitant163.0%
- 23Acyclovir2,5802.3%
- 24Ciltacabtagene Autoleucel1032.0%
Related reactions
Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.
- Immune Effector Cell-associated Neurotoxicity Syndrome5 shared · 0.15
- Neuropathy Peripheral12 shared · 0.11
- Hypogammaglobulinaemia3 shared · 0.11
- Cytokine Release Syndrome5 shared · 0.09
- Neurotoxicity3 shared · 0.09
- Cytopenia3 shared · 0.09
- Neutropenia19 shared · 0.08
- Corneal Disorder2 shared · 0.08
- Corneal Epithelial Microcysts2 shared · 0.08
- Night Blindness2 shared · 0.08
Literature
Recent PubMed references pinned to Multiple Myeloma as a MeSH major topic. About the reaction term itself — not about any specific drug.
- Clinical Characteristics, Treatment Patterns, and Prognosis of Central Nervous System Involvement in Multiple Myeloma: A Multicenter Retrospective Study From China.Cancer medicine · 2026 · Li W, Tian W, Ma J, et al.PMID 42204788DOI 10.1002/cam4.71986
- Low-dose Andrographolide Synergizes With Cytarabine or Vincristine in Plasma Cell Neoplasm Cell Lines.Anticancer research · 2026 · Doi H, Akiyama H, Matsui T, et al.PMID 42203354DOI 10.21873/anticanres.18181
- Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.Science translational medicine · 2026 · Sperling AS, Derman BA, Nikiforow S, et al.PMID 42202046DOI 10.1126/scitranslmed.adx1799
- Application of the New IMWG/IMS High-Risk Classification for Multiple Myeloma: Analysis of a Large Real-World Romanian Cohort.International journal of molecular sciences · 2026 · Badelita SN, Barbu S, Calugaru OT, et al.PMID 42196600DOI 10.3390/ijms27104620
- Microenvironmental Drivers of Bone Disease in Multiple Myeloma: Oxidative Stress, Sterile Inflammation, Autophagy-Lysosomal Remodeling, and the Iron-Lipid Peroxidation Axis.Biomolecules · 2026 · Nasso ME, Bottaro A, Fazio M, et al.PMID 42194058DOI 10.3390/biom16050710
- APN Inhibitor Bestatin Induces MM Cell Differentiation Through the CD79B/BTK/STAT3 Pathway.Cells · 2026 · Wang X, Fang C, Li S, et al.PMID 42193957DOI 10.3390/cells15100949
Note. FAERS reports are voluntarily submitted and are NOT incidence rates, signals, or causal evidence. Counts reflect reporting volume, not how often a reaction occurs. Reference statistics only.